Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Hammad Ali FadlalmolaMuayad Saud AlbadraniAmal Mohamed ElhuseinWahieba E MohamedsalihVeerabhadra D S SwamyDaniel Mon MamanaoPublished in: Dermatology research and practice (2021)
Abrocitinib in dose 100 mg or 200 mg is an effective, well-tolerated, and promising drug in treating patients with moderate-to-severe atopic dermatitis. However, the analysis favored the efficacy of abrocitinib 200 mg over 100 mg, but side effects such as nausea and headache are likely to occur more with 200 mg.